Comparison of the effects of AcSDKP, thymosin beta4, macrophage inflammatory protein 1alpha and transforming growth factor beta on human leukemic cells.

abstract：:The impact of health insurance with inequitable rituximab coverage on the survival of patients with diffuse large B-cell lymphoma (DLBCL) has never been reported. We conducted a nationwide multicenter analysis on the outcome of 553 adult patients consecutively diagnosed with DLBCL between July 2003 and June 2006, in w...

journal_title：Leukemia & lymphoma

authors： Intragumtornchai T,Bunworasate U,Siritanaratkul N,Khuhapinant A,Nawarawong W,Norasetthada L,Lekhakula A,Rujirojindakul P,Sirijerachai C,Chansung K,Suwanban T,Chuncharunee S,Niparuck P,Wongkhantee S,Mongkonsritragoon W,Numbe

更新日期：2013-01-01 00:00:00

abstract：:Primary central nervous system lymphoma (PCNSL) is an aggressive neoplasm with a poor prognosis. Early studies of whole brain radiation therapy (WBRT) alone revealed a robust initial response but high rates of local recurrence with long-term follow-up. The addition of high-dose methotrexate (HDMTX)-based chemotherapy ...

journal_title：Leukemia & lymphoma

authors： Milgrom SA,Yahalom J

更新日期：2015-05-01 00:00:00

abstract：:Anthracycline uptake could be affected by efflux pumps of the ABC family. The influence of 7 SNPs of ABC genes was evaluated in 225 adult de novo acute myeloid leukemia (AML) patients. After multivariate logistic regression there were no significant differences in complete remission, though induction death was associa...

journal_title：Leukemia & lymphoma

authors： Megías-Vericat JE,Montesinos P,Herrero MJ,Moscardó F,Bosó V,Rojas L,Martínez-Cuadrón D,Hervás D,Boluda B,García-Robles A,Rodríguez-Veiga R,Martín-Cerezuela M,Cervera J,Sendra L,Sanz J,Miguel A,Lorenzo I,Poveda JL,Sanz

更新日期：2017-05-01 00:00:00

abstract：:In a woman with chronic lymphocytic leukemia (CLL), a plasmacytoma developed on the back region after four years. CLL cases complicated with plasmacytoma are rare. In the present case, the plasmacytoma showed kappa cytoplasmic immunoglobulin (Ig), and the CLL showed gamma lambda surface Ig. To reveal the clonal origin...

journal_title：Leukemia & lymphoma

authors： Yahata N,Iwase O,Iwama H,Tauchi T,Kawanishi Y,Serizawa H,Ohyashiki K

更新日期：2000-09-01 00:00:00

abstract：:Consolidation chemotherapy in acute myeloid leukemia (AML) aims at eradicating residual leukemic cells and mostly comprises high-dose cytarabine with or without the addition of anthracyclines, including daunorubicin. Immunogenic cell death (ICD) may contribute to the efficacy of anthracyclines in solid cancer, but the...

journal_title：Leukemia & lymphoma

authors： Aurelius J,Möllgård L,Kiffin R,Ewald Sander F,Nilsson S,Thorén FB,Hellstrand K,Martner A

更新日期：2019-11-01 00:00:00

abstract：:Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, but is gratifying to treat for both physicians and patients. During the 50 years since its initial description as a clinical entity, hematologists have been fascinated by the bizarre appearance of the malignant cell with its hair-like projections...

journal_title：Leukemia & lymphoma

authors： Tallman MS,Polliack A

更新日期：2009-10-01 00:00:00

abstract：:Conventional cytogenetic analysis is limited in the evaluation of plasma cell disorders because, relative to normal hematopoietic elements, plasma cells divide slowly. Moreover, it is difficult to know whether abnormal metaphases originate from malignant plasma cells or myeloid cells harboring other abnormalities. We ...

journal_title：Leukemia & lymphoma

authors： Fonseca R,Rajkumar SV,Ahmann GJ,Jalal SM,Hoyer JD,Gertz MA,Kyle RA,Greipp PR,Dewald GW

更新日期：2000-10-01 00:00:00

abstract：:Recent advances in the treatment of patients with non-Hodgkin lymphoma have driven a paradigm shift from standard chemotherapy to an ever-expanding choice of targeted agents and combinations. As an orally bioavailable immunomodulator with antineoplastic, immunologic, and antiproliferative activity in B-cell lymphoma, ...

journal_title：Leukemia & lymphoma

authors： Galanina N,Petrich A,Nabhan C

更新日期：2016-07-01 00:00:00

abstract：:The association of leukocytoclastic vasculitis or dermatomyositis with malignancies has been reported. We describe a patient who developed a skin rash, histologically compatible with dermatomyositis, which during the course of the disease switched to leukocytoclastic vasculitis, which was accompanied with peripheral b...

journal_title：Leukemia & lymphoma

authors： Tzavara V,Stamoulis K,Aroni KG,Kordossis T,Boki KA

更新日期：1997-04-01 00:00:00

abstract：:Tyrosine kinase inhibitors (TKIs) are teratogenic. Chronic myeloid leukemia (CML) is increasingly identified in younger patients who wish to conceive, the management of CML during pregnancy is challenging. We reviewed 51 pregnancies involving 37 patients (30 women, 10 with >1 pregnancy and 7 men) who were either diagn...

journal_title：Leukemia & lymphoma

authors： Assi R,Kantarjian H,Keating M,Pemmaraju N,Verstovsek S,Garcia-Manero G,Ravandi F,Borthakur G,Dahl J,Jabbour E,Cortes JE

更新日期：2020-12-07 00:00:00

abstract：:The quinazoline antifolate N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N- methylamino]-2-thenoyl)-L-glutamic acid (ZD1694; Tomudex) is a potent inhibitor of thymidylate synthase and causes cell death through disruption of DNA synthesis and repair by blocking the obligatory thymidine nucleotide synthesis....

journal_title：Leukemia & lymphoma

authors： Ek O,Reaman GH,Crankshaw DL,Chelstrom LM,Myers DE,Uckun FM

更新日期：1998-02-01 00:00:00

abstract：:The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80-90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure f...

journal_title：Leukemia & lymphoma

authors： Stahl M,Tallman MS

更新日期：2019-12-01 00:00:00

abstract：:Chronic myeloid leukemia therapy has remarkably improved with the use of frontline BCR-ABL kinase inhibitors such that newly diagnosed patients have minimal disease manifestations or progression. Effective control of disease may also set the stage for eventual 'cure' of this leukemia. However, the existence of Philade...

journal_title：Leukemia & lymphoma

authors： Donato NJ,Peterson LF

更新日期：2011-02-01 00:00:00

abstract：:In order to assess the contribution of FC to the diagnosis of lymph node disorders we retrospectively compared the pathological and the FC diagnosis made in 118 consecutive lymph node biopsies. Pathological diagnosis included non malignant conditions (n = 43), B-cell Non Hodgkin lymphoma (NHL) (n = 30), T-cell NHL (1 ...

journal_title：Leukemia & lymphoma

authors： Ravoet C,Demartin S,Gerard R,Dehon M,Peny MO,Petit B,Delannoy A,Husson B

更新日期：2004-08-01 00:00:00

abstract：:The purpose of this study was to determine the activity of topotecan given by 21-day continuous infusion in patients previously treated with one prior therapy for a diffuse large-cell lymphoma or immunoblastic lymphoma. Patients with appropriate histology and measurable disease who had been treated with one prior chem...

journal_title：Leukemia & lymphoma

authors： Wiernik PH,Li H,Weller E,Hochster HS,Horning SJ,Nazeer T,Gordon LI,Habermann TM,Minniti CJ Jr,Shapiro GR,Cassileth PA

更新日期：2012-06-01 00:00:00

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:Most human myeloid leukemias express both class I and class II HLA and it has been postulated that leukemia-associated peptides are presented by those molecules. It is possible, however, that leukemia cells escape the immune surveillance by lacking expression of "costimulatory" molecules required for activating the im...

journal_title：Leukemia & lymphoma

authors： Matsumoto K,Anasetti C

更新日期：1999-11-01 00:00:00

abstract：:Ruxolitinib is the only therapy with an approved indication for myelofibrosis (MF), a myeloproliferative neoplasm associated with progressive bone marrow fibrosis and extramedullary hematopoiesis. Although the pivotal phase 3 COMFORT studies included only patients with intermediate-2 or high-risk MF, the US indication...

journal_title：Leukemia & lymphoma

authors： Harrison CN,Talpaz M,Mead AJ

更新日期：2016-10-01 00:00:00

abstract：:The objective of this study was to assess the impact of the primary prophylaxis of granulocyte colony-stimulating factor (G-CSF) in the management of childhood B-cell non-Hodgkin lymphoma (B-NHL). Patients with advanced-stage mature B-NHL were randomized to receive prophylactic G-CSF (G-CSF+) or not receive G-CSF (G-C...

journal_title：Leukemia & lymphoma

authors： Tsurusawa M,Watanabe T,Gosho M,Mori T,Mitsui T,Sunami S,Kobayashi R,Fukano R,Tanaka F,Fujita N,Inada H,Sekimizu M,Koh K,Kosaka Y,Komada Y,Saito AM,Nakazawa A,Horibe K,lymphoma committee of the Japanese Pediatric Leuke

更新日期：2016-07-01 00:00:00

abstract：:Patients with higher-risk MDS have an abysmal survival record and should be started immediately on therapy, the most common of which being the hypomethylating agents, azacitidine or decitabine. Patients achieving a complete or partial response or hematologic improvement have been shown in two separate studies to have ...

journal_title：Leukemia & lymphoma

authors： Sekeres MA

更新日期：2015-01-01 00:00:00

abstract：:Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...

journal_title：Leukemia & lymphoma

authors： Nagel S,Venturini L,Meyer C,Kaufmann M,Scherr M,Drexler HG,Macleod RA

更新日期：2011-02-01 00:00:00

abstract：:A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening ...

journal_title：Leukemia & lymphoma

authors： Kaeda J,Ringel F,Oberender C,Mills K,Quintarelli C,Pane F,Koschmieder S,Slany R,Schwarzer R,Saglio G,Hemmati P,van Lessen A,Amini L,Gresse M,Vagge E,Burmeister T,Serra A,Carson A,Schwarz M,Westermann J,Jundt F,D

更新日期：2015-07-01 00:00:00

abstract：:The efficacy of All-Trans Retinoic Acid (Atra) and Arsenic Trioxide (As(2)O(3)) in the treatment of Acute Promyelocytic Leukemia (APL) is well known. Further, these drugs inhibit cell growth and induce apoptosis in several cell lines, but few data are reported on leukemic blasts. The aim of this study was to evaluate ...

journal_title：Leukemia & lymphoma

authors： Cosenza M,Civallero M,Sacchi S,Marcheselli R,Pozzi S

更新日期：2005-02-01 00:00:00

abstract：:Disparities in cancer care have been documented. However, less is known about the disparities in diffuse large B-cell lymphoma (DLBCL). We reviewed the Surveillance, Epidemiology and End Results database to evaluate disparities in receipt of radiotherapy (RT) and relative survival among patients diagnosed with stage I...

journal_title：Leukemia & lymphoma

authors： Shah BK,Bista A,Shafii B

更新日期：2015-04-01 00:00:00

abstract：:The aim of this research was to determine the serum dipeptidyl peptidase IV (DPPIV) activity as well as the percentages of CD26 + lymphocytes and CD26 + overall white blood cells in patients with hematological malignancies: non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), leukemia, plasmacytoma and multiple myeloma,...

journal_title：Leukemia & lymphoma

authors： Matić IZ,Đorđević M,Đorđić M,Grozdanić N,Damjanović A,Kolundžija B,Vidović A,Bila J,Ristić S,Mihaljević B,Tomin D,Milanović N,Ristić D,Purić M,Gavrilović D,Cordero OJ,Juranić ZD

更新日期：2013-12-01 00:00:00

abstract：:Little is known about the mechanism(s) by which alpha-interferon (aIFN), when used as a biotherapeutic agent, suppresses the malignant cells and restores the normal phenotype of cells in patients with hairy cell leukemia (HCL). In previous studies using scanning electron microscopy (SEM) we found that alFN induced uni...

journal_title：Leukemia & lymphoma

authors： Gamliel H,Gurfel D,Wu SH,Salzberg S,Golomb HM

更新日期：1990-01-01 00:00:00

abstract：:The human analogue of the mouse double minute-2 (MDM-2) protein binds to p53 protein and abrogates its tumor-suppressing activity. MDM-2 overexpression may represent an alternative mechanism to p53 mutation for escaping the p53-mediated growth control. Interestingly, multiple MDM-2 protein isoforms have been described...

journal_title：Leukemia & lymphoma

authors： Bueso-Ramos CE,Manshouri T,Haidar MA,Huh YO,Keating MJ,Albitar M

更新日期：1995-03-01 00:00:00

abstract：:Treatment of hairy cell leukemia (HCL), a disease first described in 1958, has evolved from splenectomy, which resulted in a normalization of blood counts in about 41% of patients and an improvement in the remaining 59% of patients but with a time to failure of only approximately 19 months, through treatment in the ea...

journal_title：Leukemia & lymphoma

authors： Golomb HM

更新日期：2011-06-01 00:00:00

abstract：:Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...

journal_title：Leukemia & lymphoma

authors： Liliemark EK,Liliemark J,Pettersson B,Gruber A,Björkholm M,Peterson C

更新日期：1993-07-01 00:00:00

abstract：:Tumor necrosis factor alpha (TNF-alpha) and lymphotoxin alpha (LT-alpha) have been shown to play an important role in the pathogenesis of limphoproliferative disease. Both cytokines regulate cell-survival and cell-death in leukemic cells. TNF-alpha and LT-alpha are highly produced in chronic lymphotic leukemia (CLL) a...

journal_title：Leukemia & lymphoma

authors： Jevtovic-Stoimenov T,Kocic G,Pavlovic D,Macukanovic-Golubovic L,Marjanovic G,Djordjevic V,Tosić N,Pavlović S

更新日期：2008-11-01 00:00:00